Comparative Pharmacology
Head-to-head clinical analysis: NITROGLYCERIN IN DEXTROSE 5 versus NITROLINGUAL PUMPSPRAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NITROGLYCERIN IN DEXTROSE 5 versus NITROLINGUAL PUMPSPRAY.
NITROGLYCERIN IN DEXTROSE 5% vs NITROLINGUAL PUMPSPRAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitroglycerin is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing cGMP levels and causing venous and arterial dilation.
Nitroglycerin is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase and increasing cyclic guanosine monophosphate (cGMP), leading to vasodilation of peripheral arteries and veins. This reduces preload and afterload, decreasing myocardial oxygen demand.
Intravenous infusion: Initial 5 mcg/min, titrate by 5 mcg/min every 3-5 minutes to hemodynamic effect; usual maintenance 10-200 mcg/min. Sublingual: 0.3-0.6 mg every 5 minutes up to 3 doses. Topical: 1-2 inches every 8 hours.
1-2 sprays sublingually at onset of angina; may repeat every 5 minutes up to 3 doses in 15 minutes. Prophylaxis: 1 spray 5-10 minutes before activity.
None Documented
None Documented
Terminal elimination half-life: 1–4 minutes; clinical context: rapid clearance due to extensive metabolism by glutathione-S-transferase and glutathionylation.
Terminal elimination half-life of nitroglycerin is 1–4 minutes; however, clinical hemodynamic effects last longer due to active metabolites and tissue distribution.
Renal: ~33% as intact drug; hepatic metabolism accounts for >90% of clearance; biliary/fecal: negligible.
Renal excretion of inactive metabolites (nitrate ions) accounts for approximately 80% of elimination; biliary/fecal excretion is minimal (less than 5%).
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator